Survival Advantage Associated with Decrease in Stage at Detection from Stage IIIC to Stage IIIA Epithelial Ovarian Cancer.

J Oncol · 2014 · PMC4165880 · PMID 25254047

Europe PMC DOI

hedged sentence

0.0001

closest p · 0.0× alpha

0.0001

boldest claim

The sentences

highly significantP < 0.0001actually significant

However, the same 19% survival advantage observed between Stage IIIA cases and Stage IIIC cases treated at SEER institutions was highly significant ( P < 0.0001) when a greater number of patients were included in both Stage III subgroups.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.